ReviewHandbook of clinical neurology2022
Better language through chemistry: Augmenting speech-language therapy with pharmacotherapy in the treatment of aphasia.
Review in Handbook of clinical neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 13 citations in OpenAlex.
- Efficacy and safety of DL-3-N-butylphthalide in the treatment of ischemic poststroke aphasia: A randomized clinical trial.Annals of clinical and translational neurology · 2024Trial
- Effect of Acupuncture vs Sham Acupuncture on Patients With Poststroke Motor Aphasia: A Randomized Clinical Trial.JAMA network open · 2024Trial
- Molecular and cellular correlates of human cortical lateralization.Communications biology · 2026Article
- The Tip-of-the-Tongue Phenomenon: Cognitive, Neural, and Neurochemical Perspectives.Biomedicines · 2026Review
- Transcranial Magnetic Stimulation Combined with Speech-Language Therapy for Post-Stroke Aphasia Recovery: A Systematic Review and Network Meta-Analysis.Therapeutics and clinical risk management · 2026Review
- The molecular and cellular underpinnings of human brain lateralization.bioRxiv : the preprint server for biology · 2025Article
- Aphasia rehabilitation: a narrative review of adjuvant techniques.Frontiers in human neuroscience · 2025Review
- Therapies and Challenges in the Post-Stroke Aphasia Rehabilitation Arena: Current and Future Prospects.Medicina (Kaunas, Lithuania) · 2023Review
- Review
- Supporting Post-Stroke Language and Cognition with Pharmacotherapy: Tools for Each Phase of Care.Current neurology and neuroscience reports · 2023Review
- Understanding recovery of language after stroke: insights from neurovascular MRI studies.Frontiers in language sciences · 2023Article
- Reversing the Ruin: Rehabilitation, Recovery, and Restoration After Stroke.Current neurology and neuroscience reports · 2022Review
- Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
Speech and language therapy is the standard treatment of aphasia. However, many individuals have barriers in seeking this measure of extensive rehabilitation treatment. Investigating ways to augment therapy is key to improving poststroke language outcomes for all patients with aphasia, and pharmacotherapies provide one such potential solution. Although no medications are currently approved for the treatment of aphasia by the United States Food and Drug Administration, numerous candidate mechanisms for pharmaceutical manipulation continue to be identified based on our evolving understanding of the neurometabolic experience of stroke recovery across molecular, cellular, and functional levels of inquiry. This chapter will review evidence for catecholaminergic, glutamatergic, cholinergic, and serotonergic drug therapies and discuss future directions for both candidate drug selection and pharmacotherapy practice in people with aphasia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.